| 3.5 0.36 (11.46%) | 11-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.26  |
1-year : | 4.97 |
| Resists | First : | 3.64 |
Second : | 4.26 |
| Pivot price | 2.81 |
|||
| Supports | First : | 2.41 |
Second : | 1.65 |
| MAs | MA(5) : | 3 |
MA(20) : | 2.57 |
| MA(100) : | 1.92 |
MA(250) : | 1.95 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 88.5 |
D(3) : | 85.2 |
| RSI | RSI(14): 75 |
|||
| 52-week | High : | 3.64 | Low : | 1.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GANX ] has closed above the upper band by 3.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 117.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.4 - 3.42 | 3.42 - 3.43 |
| Low: | 2.85 - 2.86 | 2.86 - 2.88 |
| Close: | 3.12 - 3.14 | 3.14 - 3.16 |
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Sat, 29 Nov 2025
Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development - Yahoo Finance UK
Fri, 28 Nov 2025
Gain Therapeutics files prospectus supplement for $35.5 million stock offering - Investing.com
Fri, 28 Nov 2025
Gain Therapeutics Files Prospectus Supplement for Stock Offering - TradingView
Thu, 20 Nov 2025
Gain Therapeutics (Nasdaq: GANX) Reports GT-02287 Mitochondrial, Neuronal Data - Stock Titan
Mon, 17 Nov 2025
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Wed, 12 Nov 2025
Gain Therapeutics Reports Continued Progress Amid Financial Challenges - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 11.9 (%) |
| Shares Short | 911 (K) |
| Shares Short P.Month | 422 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -86.8 % |
| Return on Equity (ttm) | -261.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.1 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -5.74 |
| PEG Ratio | 0 |
| Price to Book value | 21.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|